SHELTERPharmaceuticals
Shelter Pharma Ltd — Profit & Loss Statement
₹26.83
-1.86%
Shelter Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.31 Cr | -0.08 Cr | — |
| Tax Rate For Calcs | 0.25 | 0.25 | 0.25 | 0.27 | — |
| Normalized EBITDA | 10.07 Cr | 8.58 Cr | 8.35 Cr | 3.04 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 7.24 Cr | 6.20 Cr | 5.21 Cr | 1.84 Cr | — |
| Reconciled Depreciation | 0.27 Cr | 0.25 Cr | 0.16 Cr | 0.17 Cr | — |
| Reconciled Cost Of Revenue | 37.03 Cr | 28.92 Cr | 26.66 Cr | 25.85 Cr | — |
| EBITDA | 10.07 Cr | 8.58 Cr | 7.15 Cr | 2.74 Cr | — |
| EBIT | 9.80 Cr | 8.33 Cr | 6.99 Cr | 2.57 Cr | — |
| Net Interest Income | -0.13 Cr | -0.05 Cr | -0.03 Cr | -0.08 Cr | — |
| Interest Expense | 0.13 Cr | 0.05 Cr | 55000.00 | 0.06 Cr | — |
| Normalized Income | 7.24 Cr | 6.20 Cr | 6.10 Cr | 2.06 Cr | — |
| Net Income From Continuing And Discontinued Operation | 7.24 Cr | 6.20 Cr | 5.21 Cr | 1.84 Cr | — |
| Total Expenses | 40.86 Cr | 31.70 Cr | 27.95 Cr | 27.17 Cr | — |
| Diluted NI Availto Com Stockholders | 7.24 Cr | 6.20 Cr | 5.21 Cr | 1.84 Cr | — |
| Net Income Common Stockholders | 7.24 Cr | 6.20 Cr | 5.21 Cr | 1.84 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 7.24 Cr | 6.20 Cr | 5.21 Cr | 1.84 Cr | — |
| Net Income Including Noncontrolling Interests | 7.24 Cr | 6.20 Cr | 5.21 Cr | 1.84 Cr | — |
| Net Income Continuous Operations | 7.24 Cr | 6.20 Cr | 5.21 Cr | 1.84 Cr | — |
| Tax Provision | 2.44 Cr | 2.08 Cr | 1.78 Cr | 0.67 Cr | — |
| Pretax Income | 9.68 Cr | 8.28 Cr | 6.98 Cr | 2.51 Cr | — |
| Other Non Operating Income Expenses | 55000.00 | 39000.00 | 24000.00 | 28000.00 | — |
| Net Non Operating Interest Income Expense | -0.13 Cr | -0.05 Cr | -0.03 Cr | -0.08 Cr | — |
| Interest Expense Non Operating | 0.13 Cr | 0.05 Cr | 55000.00 | 0.06 Cr | — |
| Operating Income | 9.80 Cr | 8.33 Cr | 8.21 Cr | 2.88 Cr | — |
| Operating Expense | 3.83 Cr | 2.77 Cr | 1.29 Cr | 1.32 Cr | — |
| Other Operating Expenses | 1.94 Cr | 1.66 Cr | 0.41 Cr | 0.52 Cr | — |
| Depreciation And Amortization In Income Statement | 0.27 Cr | 0.25 Cr | 0.16 Cr | 0.17 Cr | — |
| Depreciation Income Statement | 0.27 Cr | 0.25 Cr | 0.16 Cr | 0.17 Cr | — |
| Gross Profit | 13.63 Cr | 11.10 Cr | 9.50 Cr | 4.21 Cr | — |
| Cost Of Revenue | 37.03 Cr | 28.92 Cr | 26.66 Cr | 25.85 Cr | — |
| Total Revenue | 50.66 Cr | 40.02 Cr | 36.15 Cr | 30.06 Cr | — |
| Operating Revenue | 50.66 Cr | 40.02 Cr | 36.15 Cr | 30.06 Cr | — |
| Total Unusual Items | — | -0.30 Cr | -1.20 Cr | -0.31 Cr | -0.29 Cr |
| Total Unusual Items Excluding Goodwill | — | -0.30 Cr | -1.20 Cr | -0.31 Cr | -0.29 Cr |
| Rent Expense Supplemental | — | 0.00 | 0.03 Cr | 0.03 Cr | 0.03 Cr |
| Diluted Average Shares | — | 1.16 Cr | 1.16 Cr | 1.16 Cr | 1.16 Cr |
| Basic Average Shares | — | 1.16 Cr | 1.15 Cr | 1.16 Cr | 1.16 Cr |
| Diluted EPS | — | 5.36 | 4.49 | 1.59 | -0.21 |
| Basic EPS | — | 5.36 | 4.54 | 1.59 | -0.21 |
| Special Income Charges | — | -0.30 Cr | -1.20 Cr | -0.31 Cr | -0.29 Cr |
| Write Off | — | 0.30 Cr | 0.30 Cr | 0.31 Cr | 0.29 Cr |
| Total Other Finance Cost | — | 0.05 Cr | 0.02 Cr | 0.01 Cr | 36000.00 |
| Research And Development | — | 0.02 Cr | 0.04 Cr | 0.03 Cr | 0.03 Cr |
| Selling General And Administration | — | 0.09 Cr | 0.10 Cr | 0.11 Cr | 0.12 Cr |
| Selling And Marketing Expense | — | 0.04 Cr | 0.05 Cr | 0.04 Cr | 0.03 Cr |
| General And Administrative Expense | — | 0.05 Cr | 0.05 Cr | 0.07 Cr | 0.09 Cr |
| Rent And Landing Fees | — | 0.00 | 0.03 Cr | 0.03 Cr | 0.03 Cr |
| Interest Income | — | — | 0.00 | 14000.00 | 19000.00 |
| Other Special Charges | — | — | 0.90 Cr | — | — |
| Interest Income Non Operating | — | — | 0.00 | 14000.00 | 19000.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Shelter Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.